Day One Biopharmaceuticals Ownership | Who Owns Day One Biopharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Day One Biopharmaceuticals Ownership Summary


Day One Biopharmaceuticals is owned by 59.23% institutional investors, 16.94% insiders, and 23.83% retail investors. Fmr is the largest institutional shareholder, holding 9.80% of DAWN shares. State Street® SPDR® S&P® Biotech ETF is the top mutual fund, with 2.61% of its assets in Day One Biopharmaceuticals shares.

DAWN Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockDay One Biopharmaceuticals59.23%16.94%23.83%
SectorHealthcare Stocks 232.63%10.66%-143.29%
IndustryBiotech Stocks 382.12%10.42%-292.54%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr10.10M9.80%$71.19M
Blackrock funding, inc. /de8.84M8.55%$82.37M
Atlas venture life science advisors6.43M6.24%$45.33M
Vanguard group6.28M6.08%$58.55M
Blackrock4.53M5.23%$62.47M
Deerfield management company, l.p. (series c)4.71M4.57%$33.17M
State street3.24M3.14%$22.85M
Pictet asset management sa2.99M2.89%$27.87M
Vestal point capital, lp2.67M2.60%$18.86M
Braidwell lp2.18M2.12%$15.38M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Atlas venture life science advisors6.43M6.02%$45.33M
Aigh capital management1.99M4.49%$18.57M
Stonepine capital management647.38K3.71%$4.56M
Dafna capital management999.16K1.74%$7.04M
Lion point capital, lp42.00K1.68%$296.10K
Mak capital one1.45M1.57%$10.21M
Boxer capital1.19M0.86%$16.40M
Vestal point capital, lp2.67M0.85%$18.86M
Perkins capital management84.00K0.62%$782.88K
Deerfield management company, l.p. (series c)4.71M0.51%$33.17M

Top Buyers

HolderShares% AssetsChange
Mak capital one1.45M1.57%1.45M
Jefferies financial group1.12M0.05%1.12M
Deerfield management company, l.p. (series c)4.71M0.51%982.28K
Pictet asset management sa2.99M0.03%617.67K
Jane street group845.15K0.00%565.81K

Top Sellers

HolderShares% AssetsChange
Ra capital management---5.76M
Franklin resources52.73K0.00%-3.42M
Rubric capital management lp---3.38M
Estuary capital management lp---3.33M
Fairmount funds management---3.10M

New Positions

HolderShares% AssetsChangeValue
Mak capital one1.45M1.57%1.45M$10.21M
Jefferies financial group1.12M0.05%1.12M$10.45M
Jump financial272.55K0.02%272.55K$1.92M
Norges bank169.00K0.00%169.00K$1.58M
Massachusetts financial services co /ma/150.93K0.00%150.93K$1.41M

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-12.00
Northwestern mutual wealth management-14.00
Geowealth management-23.00
C m bidwell & associates-28.00
Clearstead advisors-39.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025159-7.56%61,236,176-28.40%590.86%911.11%37-33.93%
Sep 30, 2025167-1.76%83,154,2761.47%801.28%87-12.12%5410.20%
Jun 30, 2025178-6.32%86,133,5140.67%831.20%101-6.48%5210.64%
Mar 31, 202519311.56%94,051,9090.33%910.97%10813.68%4720.51%
Dec 31, 2024170-3.41%93,046,5121.26%961.06%93-8.82%408.11%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
State Street® SPDR® S&P® Biotech ETF2.69M2.61%-14.49K
Vanguard US Total Market Shares ETF2.46M2.43%522.40K
Vanguard Total Stock Mkt Idx Inv2.41M2.33%-
Polar Capital Biotech S Inc2.11M2.06%-
Pictet-Biotech P USD1.91M1.85%575.67K
iShares Russell 2000 ETF1.88M1.82%1.39M
Franklin Small Cap Growth SMA1.61M1.59%1.61M
Franklin US Small Cap Growth Equity1.61M1.59%130.60K
Franklin Biotechnology Discv A(acc)USD1.55M1.52%-
FIAM Small Cap Core Composite1.55M1.50%226.95K

Recent Insider Transactions


DateNameRoleActivityValue
Feb 17, 2026Merendino Lauren Chief Commercial OfficerSell$67.45K
Feb 17, 2026Dubow Adam Gen Counsel & SecretarySell$74.19K
Feb 17, 2026York Charles N II COO and CFOSell$70.36K
Feb 17, 2026Bender Jeremy CHIEF EXECUTIVE OFFICERSell$179.34K
Feb 17, 2026VASCONCELLES MICHAEL Head of Research and Dev.Sell$31.65K

Insider Transactions Trends


DateBuySell
2026 Q1-5
2025 Q4-4
2025 Q3-4
2025 Q2-4
2025 Q1-3

DAWN Ownership FAQ


Who Owns Day One Biopharmaceuticals?

Day One Biopharmaceuticals shareholders are primarily institutional investors at 59.23%, followed by 16.94% insiders and 23.83% retail investors. The average institutional ownership in Day One Biopharmaceuticals's industry, Biotech Stocks , is 382.12%, which Day One Biopharmaceuticals falls below.

Who owns the most shares of Day One Biopharmaceuticals?

Day One Biopharmaceuticals’s largest shareholders are Fmr (10.1M shares, 9.80%), Blackrock funding, inc. /de (8.84M shares, 8.55%), and Atlas venture life science advisors (6.43M shares, 6.24%). Together, they hold 24.58% of Day One Biopharmaceuticals’s total shares outstanding.

Does Blackrock own Day One Biopharmaceuticals?

Yes, BlackRock owns 5.23% of Day One Biopharmaceuticals, totaling 4.53M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 62.47M$. In the last quarter, BlackRock decreased its holdings by -498K shares, a -9.90% change.

Who is Day One Biopharmaceuticals’s biggest shareholder by percentage of total assets invested?

Atlas venture life science advisors is Day One Biopharmaceuticals’s biggest shareholder by percentage of total assets invested, with 6.02% of its assets in 6.43M Day One Biopharmaceuticals shares, valued at 45.33M$.

Who is the top mutual fund holder of Day One Biopharmaceuticals shares?

State Street® SPDR® S&P® Biotech ETF is the top mutual fund holder of Day One Biopharmaceuticals shares, with 2.61% of its total shares outstanding invested in 2.69M Day One Biopharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools